Publications by authors named "G B Ippoliti"
We present the Canadian Open Neuroscience Platform (CONP) portal to answer the research community's need for flexible data sharing resources and provide advanced tools for search and processing infrastructure capacity. This portal differs from previous data sharing projects as it integrates datasets originating from a number of already existing platforms or databases through DataLad, a file level data integrity and access layer. The portal is also an entry point for searching and accessing a large number of standardized and containerized software and links to a computing infrastructure.
View Article and Find Full Text PDFA data-driven controller is presented in this paper, which stems from the well known model-free adaptive control approach based on an equivalent linearized dynamical model of the plant. Inspired by the recent paper (Liu and Yang, 2019), the output tracking problem is here solved by a data-driven adaptive sliding-mode controller simultaneously ensuring prescribed performance constraints. To allow a rigorous stability analysis, the sliding variable, and the consequently derived controller, have been redesigned with respect to the inspiring paper.
View Article and Find Full Text PDFArticle Synopsis
- Ruxolitinib is an anti-inflammatory drug that targets the JAK-STAT pathway and was used to treat severe COVID-19 patients with low oxygen saturation and interstitial pneumonia without mechanical ventilation support.
- In a study involving 31 patients, significant improvements were observed after 7 days, with 80.6% showing reduced symptoms and notable decreases in inflammation markers like C-reactive protein (CRP).
- The treatment led to better oxygenation (measured by PaO2/FiO ratio) and no adverse side effects were reported, supporting the idea that addressing hyperinflammation can benefit COVID-19 patients.
Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection do exist. We performed a retrospective single-center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease 2019 (COVID-19). Of these, 297 were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 drugs because of contraindications.
View Article and Find Full Text PDFPurpose: The purpose of this study was to evaluate the impact of pre-existing diabetes on in-hospital mortality in patients admitted for Coronavirus Disease 2019 (COVID-19).
Methods: This is a single center, retrospective study conducted at Policlinico di Monza hospital, located in the Lombardy region, Northern Italy. We reviewed medical records of 373 consecutive adult patients who were hospitalized with COVID-19 between February 22 and May 15, 2020.